Tweet
RESEARCH ARTICLE
Excess risk for acute myocardial infarction mortality during the COVID-19 pandemic
Yee Hui Yeo,Maggie Wang,Xinyuan He,Fan Lv,Yue Zhang,Jian Zu,Mei Li,Yang Jiao,Joseph E. Ebinger,Jignesh K. Patel,Susan Cheng,Fanpu Ji
First published: 29 September 2022
Yee Hui Yeo, Maggie Wang, and Xinyuan He contributed equally to this study.
Susan Cheng and Fanpu Ji are co-senior authors.
Read the full text
PDFTOOLS
SHARE
Abstract
The COVID-19 pandemic has had a detrimental impact on the healthcare system. Our study armed to assess the extent and the disparity in excess acute myocardial infarction (AMI)-associated mortality during the pandemic, through the recent Omicron outbreak. Using data from the CDC's National Vital Statistics System, we identified 1 522 669 AMI-associated deaths occurring between 4/1/2012 and 3/31/2022. Accounting for seasonality, we compared age-standardized mortality rate (ASMR) for AMI-associated deaths between prepandemic and pandemic periods, including observed versus predicted ASMR, and examined temporal trends by demographic groups and region. Before the pandemic, AMI-associated mortality rates decreased across all subgroups. These trends reversed during the pandemic, with significant rises seen for the youngest-aged females and males even through the most recent period of the Omicron surge (10/2021–3/2022). The SAPC in the youngest and middle-age group in AMI-associated mortality increased by 5.3% (95% confidence interval [CI]: 1.6%–9.1%) and 3.4% (95% CI: 0.1%–6.8%), respectively. The excess death, defined as the difference between the observed and the predicted mortality rates, was most pronounced for the youngest (25–44 years) aged decedents, ranging from 23% to 34% for the youngest compared to 13%–18% for the oldest age groups. The trend of mortality suggests that age and sex disparities have persisted even through the recent Omicron surge, with excess AMI-associated mortality being most pronounced in younger-aged adults.
CONFLICTS OF INTEREST
Dr. S. Cheng has received consulting fees from Zogenix outside of the submitted work. Dr. F. Ji has received speaker fees from Gilead Sciences, MSD, and Ascletis, in addition to consulting or advisory board fees from Gilead and MSD, all outside of the submitted work. The remaining authors declare no conflict of interest.